Pilot study on the efficacy of a novel questionnaire for assessing psychological health in patients with chronic rhinosinusitis with nasal polyps treated with biologics

Background/Objectives: Chronic rhinosinusitis with nasal polyps (CRSwNP)represents a debilitating disease with significant morbidity and decreased quality of life(QoL). The introduction of biologics in its management has allowed new therapeuticoptions, and Dupilumab represents the first approved biologic. This study aims to evaluatea possible relationship between the clinical response to biological therapy andmental healthin patients with severe CRSwNP. Methods: This is a multicenter study conducted at theOtolaryngology departments of three major Italian health institutions. Participants werepatients with CRSwNP treated with Dupilumab. Patients were assessed at baseline andduring treatment by submitting them to a survey consisting of a dedicated questionnairefocused on psychological health and two patient-reported outcome measures (PROMs):the 22-item Sino-Nasal Outcome Test (SNOT-22) and a Visual Analogue Scale (VAS) fornasal symptoms. Results: 86 patients were included in the study (58 males and 28 females;mean age: 58.2 years). There was a significant improvement in both symptoms and QoL,with an enhanced psychological state observed in patients after the first administrationand within the first months of therapy. Conclusions: This study evaluated the possiblecorrelations between Dupilumab treatment and improvements in mental health in patientswith CRSwNP, as assessed through a survey, and clinical conditions, assessed throughSNOT-22 and VAS. Our findings showed that Dupilumab not only improved clinicalsymptoms but also had a positive impact on patients’ mental health, with benefits observedalready after the first administration and the first months of therapy. This survey highlightsthe relevance of psychological well-being and its implications for patients with chronicdiseases such as CRSwNP.